Details of the Drug

General Information of Drug (ID: DMAT8CG)

• Drug Name: Goserelin
• Synonyms: AstraZeneca (TN); HS-2015; ZD-9393; Zoladex (TN)

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1], [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 4:
  Molecular Weight (mw); 1269.4
  Topological Polar Surface Area (xlogp); -1.5
  Rotatable Bond Count (rotbonds); 32
  Hydrogen Bond Donor Count (hbonddonor); 17
  Hydrogen Bond Acceptor Count (hbondacc); 16
• ADMET Property:
  Absorption: The drug is rapidly absorbed following subcutaneous administration [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Elimination: 20% of drug is excreted from urine in the unchanged form [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 4 - 5 hours [5]
  Metabolism: The drug is metabolized via the hepatic [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0405 micromolar/kg/day [6]
  Vd: The volume of distribution (Vd) of drug is 44.1 +/- 13.6 L [7]
• Chemical Identifiers:
  Formula: C59H84N18O14
  IUPAC Name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
  Canonical SMILES: CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
  InChI: InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
  InChIKey: BLCLNMBMMGCOAS-URPVMXJPSA-N
• Cross-matching ID:
  PubChem CID: 5311128
  ChEBI ID: CHEBI:5523
  CAS Number: 65807-02-5
  DrugBank ID: DB00014
  TTD ID: D00BCG
  VARIDT ID: DR00378

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leutinizing-hormone-releasing hormone (GNRH1)	TT0ID4A	GON1_HUMAN	Activator	[8]

Molecular Expression Atlas of This Drug

• The Studied Disease: Breast cancer
• ICD Disease Classification: 2C60-2C65

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Leutinizing-hormone-releasing hormone (GNRH1)	DTT	GNRH1	2.23E-01	0.04	0.06

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Goserelin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Eribulin.	Breast cancer [2C60-2C6Y]	[15]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Lapatinib.	Breast cancer [2C60-2C6Y]	[15]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Tamoxifen.	Breast cancer [2C60-2C6Y]	[15]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Goserelin and Toremifene.	Breast cancer [2C60-2C6Y]	[16]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Bosutinib.	Breast cancer [2C60-2C6Y]	[15]

Coadministration of a Drug Treating the Disease Different from Goserelin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Goserelin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[17]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Midostaurin.	Acute myeloid leukaemia [2A60]	[15]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Idarubicin.	Acute myeloid leukaemia [2A60]	[15]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Daunorubicin.	Acute myeloid leukaemia [2A60]	[15]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Oliceridine.	Acute pain [MG31]	[15]
Terfenadine	DM4KLPT	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[15]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Tacrine.	Alzheimer disease [8A20]	[16]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Galantamine.	Alzheimer disease [8A20]	[16]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Rivastigmine.	Alzheimer disease [8A20]	[16]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Donepezil.	Alzheimer disease [8A20]	[16]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Goserelin and Metronidazole.	Amoebiasis [1A36]	[18]
Ranolazine	DM0C9IL	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Ranolazine.	Angina pectoris [BA40]	[15]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Goserelin and Ivabradine.	Angina pectoris [BA40]	[15]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Goserelin and Bepridil.	Angina pectoris [BA40]	[16]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Goserelin and Dronedarone.	Angina pectoris [BA40]	[16]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Goserelin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[19]
Hydroxyzine	DMF8Y74	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[15]
Promazine	DMZAL7W	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Promazine.	Appearance/behaviour symptom [MB23]	[15]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Cilostazol.	Arterial occlusive disease [BD40]	[15]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Voriconazole.	Aspergillosis [1F20]	[15]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Posaconazole.	Aspergillosis [1F20]	[15]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Levalbuterol.	Asthma [CA23]	[20]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Terbutaline.	Asthma [CA23]	[21]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Pirbuterol.	Asthma [CA23]	[21]
Isoetharine	DMITSEH	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Isoetharine.	Asthma [CA23]	[21]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Salbutamol.	Asthma [CA23]	[20]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Formoterol.	Asthma [CA23]	[21]
Atomoxetine	DM5L6HI	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[15]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[15]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[15]
Oxytocin	DMDL27I	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Oxytocin.	Autism spectrum disorder [6A02]	[15]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[15]
Erythromycin	DM4K7GQ	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Erythromycin.	Bacterial infection [1A00-1C4Z]	[15]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Goserelin and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Goserelin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Moxifloxacin	DMU8V4S	Major	Increased risk of prolong QT interval by the combination of Goserelin and Moxifloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Telithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Retigabine.	Behcet disease [4A62]	[15]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Goserelin and Grepafloxacin.	Bronchitis [CA20]	[22]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Goserelin and Sotalol.	Cardiac arrhythmia [BC9Z]	[16]
Dofetilide	DMPN1TW	Major	Increased risk of prolong QT interval by the combination of Goserelin and Dofetilide.	Cardiac arrhythmia [BC9Z]	[16]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[15]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Oxaliplatin.	Colorectal cancer [2B91]	[15]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Halothane.	Corneal disease [9A76-9A78]	[15]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Propofol.	Corneal disease [9A76-9A78]	[24]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Sevoflurane.	Corneal disease [9A76-9A78]	[15]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Probucol.	Coronary atherosclerosis [BA80]	[15]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Goserelin and Methadone.	Cough [MD12]	[16]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Clofazimine.	Crohn disease [DD70]	[15]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Goserelin and Mifepristone.	Cushing syndrome [5A70]	[16]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Goserelin and Pasireotide.	Cushing syndrome [5A70]	[16]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Osilodrostat.	Cushing syndrome [5A70]	[15]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Sertraline.	Depression [6A70-6A7Z]	[15]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Trimipramine.	Depression [6A70-6A7Z]	[15]
Imipramine	DM2NUH3	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Imipramine.	Depression [6A70-6A7Z]	[15]
Fluoxetine	DM3PD2C	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Fluoxetine.	Depression [6A70-6A7Z]	[15]
Nortriptyline	DM4KDYJ	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Nortriptyline.	Depression [6A70-6A7Z]	[15]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Goserelin and Escitalopram.	Depression [6A70-6A7Z]	[16]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Clomipramine.	Depression [6A70-6A7Z]	[15]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Trazodone.	Depression [6A70-6A7Z]	[15]
Amitriptyline	DMK7F9S	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Amitriptyline.	Depression [6A70-6A7Z]	[15]
Amoxapine	DMKITQE	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Amoxapine.	Depression [6A70-6A7Z]	[15]
Mirtazapine	DML53ZJ	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Mirtazapine.	Depression [6A70-6A7Z]	[15]
Protriptyline	DMNHTZI	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Protriptyline.	Depression [6A70-6A7Z]	[15]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Doxepin.	Depression [6A70-6A7Z]	[15]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Maprotiline.	Depression [6A70-6A7Z]	[15]
Venlafaxine	DMR6QH0	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Venlafaxine.	Depression [6A70-6A7Z]	[15]
Citalopram derivative 1	DMITX1G	Major	Increased risk of prolong QT interval by the combination of Goserelin and Citalopram derivative 1.	Discovery agent [N.A.]	[16]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[15]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Deutetrabenazine.	Dystonic disorder [8A02]	[15]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Ingrezza.	Dystonic disorder [8A02]	[15]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Solifenacin.	Functional bladder disorder [GC50]	[15]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Pentamidine.	Fungal infection [1F29-1F2F]	[15]
Fluconazole	DMOWZ6B	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Fluconazole.	Fungal infection [1F29-1F2F]	[15]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Ketoconazole.	Fungal infection [1F29-1F2F]	[15]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Goserelin and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[16]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Goserelin and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Goserelin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[15]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[16]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Goserelin and Crizotinib.	Lung cancer [2C25]	[27]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Goserelin and Ceritinib.	Lung cancer [2C25]	[16]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Goserelin and Osimertinib.	Lung cancer [2C25]	[28]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Goserelin and Selpercatinib.	Lung cancer [2C25]	[15]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Goserelin and Lumefantrine.	Malaria [1F40-1F45]	[18]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Goserelin and Halofantrine.	Malaria [1F40-1F45]	[29]
Chloroquine	DMSI5CB	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Chloroquine.	Malaria [1F40-1F45]	[15]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Hydroxychloroquine.	Malaria [1F40-1F45]	[15]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Quinine.	Malaria [1F40-1F45]	[15]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Primaquine.	Malaria [1F40-1F45]	[15]
Mefloquine	DMWT905	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Mefloquine.	Malaria [1F40-1F45]	[15]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[15]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Goserelin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[30]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Goserelin and Vemurafenib.	Melanoma [2C30]	[16]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Goserelin and Panobinostat.	Multiple myeloma [2A83]	[31]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Thalidomide.	Multiple myeloma [2A83]	[18]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Goserelin and Siponimod.	Multiple sclerosis [8A40]	[18]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Goserelin and Fingolimod.	Multiple sclerosis [8A40]	[16]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Goserelin and Ozanimod.	Multiple sclerosis [8A40]	[32]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Romidepsin.	Mycosis fungoides [2B01]	[15]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Goserelin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[16]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[15]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Goserelin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[33]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Goserelin and Droperidol.	Nausea/vomiting [MD90]	[16]
Prochlorperazine	DM53SRA	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Prochlorperazine.	Nausea/vomiting [MD90]	[15]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Promethazine.	Nausea/vomiting [MD90]	[15]
Palonosetron	DMBHMOX	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Palonosetron.	Nausea/vomiting [MD90]	[15]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Granisetron.	Nausea/vomiting [MD90]	[15]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Goserelin and Dolasetron.	Nausea/vomiting [MD90]	[16]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Ondansetron.	Nausea/vomiting [MD90]	[15]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Entrectinib.	Non-small cell lung cancer [2C25]	[15]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Goserelin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[15]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Lofexidine.	Opioid use disorder [6C43]	[15]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Rucaparib.	Ovarian cancer [2C73]	[15]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Dextropropoxyphene.	Pain [MG30-MG3Z]	[15]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Buprenorphine.	Pain [MG30-MG3Z]	[15]
Tramadol	DMRQD04	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Tramadol.	Pain [MG30-MG3Z]	[15]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Triclabendazole.	Parasitic worm infestation [1F90]	[15]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Pimavanserin.	Parkinsonism [8A00]	[15]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Apomorphine.	Parkinsonism [8A00]	[15]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Famotidine.	Peptic ulcer [DA61]	[18]
Vasopressin	DMQ2FPC	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Vasopressin.	Pituitary gland disorder [5A60-5A61]	[15]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Goserelin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[34]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Goserelin and Lefamulin.	Pneumonia [CA40]	[35]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Ritodrine.	Preterm labour/delivery [JB00]	[21]
Alfuzosin	DMZVMKF	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Alfuzosin.	Prostate hyperplasia [GA90]	[15]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[15]
Fluphenazine	DMIT8LX	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Fluphenazine.	Psychotic disorder [6A20-6A25]	[15]
Triflupromazine	DMKFQJP	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Triflupromazine.	Psychotic disorder [6A20-6A25]	[15]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Sorafenib.	Renal cell carcinoma [2C90]	[15]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Goserelin and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[23]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Quetiapine.	Schizophrenia [6A20]	[15]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Goserelin and Mesoridazine.	Schizophrenia [6A20]	[16]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Goserelin and Thioridazine.	Schizophrenia [6A20]	[16]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Aripiprazole.	Schizophrenia [6A20]	[18]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Goserelin and Iloperidone.	Schizophrenia [6A20]	[16]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Paliperidone.	Schizophrenia [6A20]	[15]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Goserelin and Haloperidol.	Schizophrenia [6A20]	[16]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Perphenazine.	Schizophrenia [6A20]	[15]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Chlorpromazine.	Schizophrenia [6A20]	[15]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Goserelin and Clozapine.	Schizophrenia [6A20]	[16]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Trifluoperazine.	Schizophrenia [6A20]	[15]
Ziprasidone	DMM58JY	Major	Increased risk of prolong QT interval by the combination of Goserelin and Ziprasidone.	Schizophrenia [6A20]	[16]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Risperidone.	Schizophrenia [6A20]	[15]
Olanzapine	DMPFN6Y	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Olanzapine.	Schizophrenia [6A20]	[18]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Goserelin and Amisulpride.	Schizophrenia [6A20]	[36]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Asenapine.	Schizophrenia [6A20]	[15]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Goserelin and Pimozide.	Schizophrenia [6A20]	[15]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Vardenafil.	Sexual dysfunction [HA00-HA01]	[15]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Goserelin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[16]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Goserelin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[16]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Pitolisant.	Somnolence [MG42]	[15]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[15]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Goserelin and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[16]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Goserelin and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[16]
Zithromax	DMN4H2O	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Zithromax.	Syphilis [1A61-1A6Z]	[15]
Anagrelide	DMSQ8MD	Major	Increased risk of prolong QT interval by the combination of Goserelin and Anagrelide.	Thrombocytosis [3B63]	[16]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Lenvatinib.	Thyroid cancer [2D10]	[15]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Goserelin and Cabozantinib.	Thyroid cancer [2D10]	[15]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Goserelin and Papaverine.	Tonus and reflex abnormality [MB47]	[37]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Tizanidine.	Tonus and reflex abnormality [MB47]	[15]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Tacrolimus.	Transplant rejection [NE84]	[15]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[15]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[15]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Goserelin and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[16]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Goserelin and Procainamide.	Ventricular tachyarrhythmia [BC71]	[16]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[15]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Goserelin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[15]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Goserelin and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[16]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3879).
• [2] Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Clin Breast Cancer. 2007 Feb;7(6):455-64.
• [3] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [4] BDDCS applied to over 900 drugs
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [8] Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
• [9] Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
• [10] The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991 Dec;165(6Pt 1):1811-7.
• [11] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011623)
• [13] EP patent application no. 2018865, Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate.
• [14] In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8898-902.
• [15] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [16] Canadian Pharmacists Association.
• [17] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [18] Cerner Multum, Inc. "Australian Product Information.".
• [19] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [20] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [21] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [22] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [23] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [24] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [25] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [26] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [27] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [28] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [29] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [30] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [31] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [32] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [33] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [34] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [35] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [36] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [37] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]